Correlation Between Viracta Therapeutics and Brainstorm Cell

Can any of the company-specific risk be diversified away by investing in both Viracta Therapeutics and Brainstorm Cell at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viracta Therapeutics and Brainstorm Cell into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Viracta Therapeutics and Brainstorm Cell Therapeutics, you can compare the effects of market volatilities on Viracta Therapeutics and Brainstorm Cell and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viracta Therapeutics with a short position of Brainstorm Cell. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viracta Therapeutics and Brainstorm Cell.

Diversification Opportunities for Viracta Therapeutics and Brainstorm Cell

0.27

Correlation Coefficient

Viracta Therapeutics  Brainstorm Cell

Modest diversification

The 3 months correlation between Viracta and Brainstorm is 0.27. Overlapping area represents the amount of risk that can be diversified away by holding Viracta Therapeutics and Brainstorm Cell Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Brainstorm Cell Ther and Viracta Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viracta Therapeutics are associated (or correlated) with Brainstorm Cell. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Brainstorm Cell Ther has no effect on the direction of Viracta Therapeutics i.e., Viracta Therapeutics and Brainstorm Cell go up and down completely randomly.

Pair Corralation between Viracta Therapeutics and Brainstorm Cell

Given the investment horizon of 90 days Viracta Therapeutics is expected to under-perform the Brainstorm Cell. In addition to that, Viracta Therapeutics is 3.52 times more volatile than Brainstorm Cell Therapeutics. It trades about -0.28 of its total potential returns per unit of risk. Brainstorm Cell Therapeutics is currently generating about -0.22 per unit of volatility. If you would invest  237.00  in Brainstorm Cell Therapeutics on December 30, 2024 and sell it today you would lose (118.00) from holding Brainstorm Cell Therapeutics or give up 49.79% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	41.94%
Values	Daily Returns

Viracta Therapeutics  vs.  Brainstorm Cell Therapeutics

Viracta Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Viracta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Brainstorm Cell Ther

Risk-Adjusted Performance

Very Weak

Over the last 90 days Brainstorm Cell Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's essential indicators remain fairly strong which may send shares a bit higher in April 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

Pair Trading with Viracta Therapeutics and Brainstorm Cell

The main advantage of trading using opposite Viracta Therapeutics and Brainstorm Cell positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viracta Therapeutics position performs unexpectedly, Brainstorm Cell can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brainstorm Cell will offset losses from the drop in Brainstorm Cell's long position.

The idea behind Viracta Therapeutics and Brainstorm Cell Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.